{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:41:51Z","timestamp":1770500511548,"version":"3.49.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.psc.2004.06.002","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T14:53:20Z","timestamp":1113836000000},"page":"627-648","source":"Crossref","is-referenced-by-count":24,"title":["Pharmacologic management of relapse prevention in addictive disorders"],"prefix":"10.1016","volume":"27","author":[{"given":"Mehmet","family":"Sofuoglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.psc.2004.06.002_bib1","first-page":"642","article-title":"Cigarette smoking among adults\u2014United States, 2000","volume":"51","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.psc.2004.06.002_bib2","series-title":"United States. Tobacco Use and Dependence Guideline Panel. Treating tobacco use and dependence","author":"Fiore","year":"2000"},{"issue":"20","key":"10.1016\/j.psc.2004.06.002_bib3","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1001\/jama.284.20.2606","article-title":"Smoking and mental illness: a population-based prevalence study","volume":"284","author":"Lasser","year":"2000","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.psc.2004.06.002_bib4","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1001\/jama.283.24.3244","article-title":"The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.psc.2004.06.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.153.10.1","article-title":"Practice guideline for the treatment of patients with nicotine dependence","volume":"153","author":"American Psychiatric Association","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/tc.12.1.21","article-title":"A meta-analysis of the efficacy of over-the-counter nicotine replacement","volume":"12","author":"Hughes","year":"2003","journal-title":"Tob Control"},{"key":"10.1016\/j.psc.2004.06.002_bib7","series-title":"The Cochrane Library, Issue 3","article-title":"Nicotine replacement therapy for smoking cessation (Cochrane Review)","author":"Silagy","year":"2004"},{"issue":"24","key":"10.1016\/j.psc.2004.06.002_bib8","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1001\/jama.1994.03510480064036","article-title":"The effectiveness of the nicotine patch for smoking cessation. A meta-analysis","volume":"271","author":"Fiore","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s002130050744","article-title":"Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms","volume":"140","author":"Hurt","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00023210-200115060-00004","article-title":"Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability","volume":"15","author":"Sweeney","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psc.2004.06.002_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1146\/annurev.pa.36.040196.003121","article-title":"Pharmacology of nicotine: addiction and therapeutics","volume":"36","author":"Benowitz","year":"1996","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.psc.2004.06.002_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/archinte.162.11.1267","article-title":"Efficacy of a nicotine lozenge for smoking cessation","volume":"162","author":"Shiffman","year":"2002","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/1462220031000158690","article-title":"Pharmacokinetics of a nicotine polacrilex lozenge","volume":"5","author":"Choi","year":"2003","journal-title":"Nicotine Tob Res"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s002130000382","article-title":"A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler","volume":"149","author":"West","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200140090-00003","article-title":"The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments","volume":"40","author":"Schneider","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib16","first-page":"395","article-title":"Bupropion: a review of its mechanism of antidepressant activity","volume":"56","author":"Ascher","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib17","first-page":"88","article-title":"Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine","volume":"288","author":"Fryer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib18","first-page":"321","article-title":"Bupropion is a nicotinic antagonist","volume":"295","author":"Slemmer","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.psc.2004.06.002_bib19","series-title":"Physicians Desk Reference","year":"2003"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199903043400903","article-title":"A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation","volume":"340","author":"Jorenby","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.psc.2004.06.002_bib21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199710233371703","article-title":"A comparison of sustained-release bupropion and placebo for smoking cessation","volume":"337","author":"Hurt","year":"1997","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.psc.2004.06.002_bib22","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4088\/JCP.v62n07a01","article-title":"Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants","volume":"62","author":"Chengappa","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"18","key":"10.1016\/j.psc.2004.06.002_bib23","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/archinte.158.18.2035","article-title":"A randomized trial of nortriptyline for smoking cessation","volume":"158","author":"Prochazka","year":"1998","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1016\/j.psc.2004.06.002_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/archpsyc.55.8.683","article-title":"Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking","volume":"55","author":"Hall","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"4676","key":"10.1016\/j.psc.2004.06.002_bib25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.6387913","article-title":"Cigarette craving, smoking withdrawal, and clonidine","volume":"226","author":"Glassman","year":"1984","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib26","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1001\/archinte.1988.00380090095023","article-title":"Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial","volume":"148","author":"Ornish","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.psc.2004.06.002_bib27","series-title":"The Cochrane Library, Issue 3","article-title":"Clonidine for smoking cessation (Cochrane Review)","author":"Gourlay","year":"2004"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib28","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/clpt.1993.205","article-title":"Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers","volume":"54","author":"Glassman","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archpsyc.59.2.115","article-title":"Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates","volume":"59","author":"Narrow","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2004.06.002_bib30","unstructured":"Harwood HJ, Fountain D, Livermore G, Lewin Group, National Institute on Drug Abuse. Office of Science Policy and Communications. Rockville (MD), National Institute on Alcohol Abuse and Alcoholism (US). Office of Policy Analysis. The economic costs of alcohol and drug abuse in the United States, 1992."},{"issue":"11","key":"10.1016\/j.psc.2004.06.002_bib31","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/jama.1986.03380110055026","article-title":"Disulfiram treatment of alcoholism. A Veterans Administration cooperative study","volume":"256","author":"Fuller","year":"1986","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","article-title":"Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study","volume":"22","author":"Besson","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1530-0277.1992.tb00648.x","article-title":"Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: a review","volume":"16","author":"Larson","year":"1992","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib34","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00002018-199920050-00003","article-title":"Safety issues concerning the use of disulfiram in treating alcohol dependence","volume":"20","author":"Chick","year":"1999","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0741-8329(86)90058-3","article-title":"Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey","volume":"3","author":"Myers","year":"1986","journal-title":"Alcohol"},{"issue":"11","key":"10.1016\/j.psc.2004.06.002_bib36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2004.06.002_bib37","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archpsyc.1996.01830030039007","article-title":"Six-month follow-up of naltrexone and psychotherapy for alcohol dependence","volume":"53","author":"O'Malley","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"10.1016\/j.psc.2004.06.002_bib39","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1176\/ajp.151.10.1463","article-title":"Naltrexone-induced alterations in human ethanol intoxication","volume":"151","author":"Swift","year":"1994","journal-title":"Am J Psychiatry"},{"issue":"24","key":"10.1016\/j.psc.2004.06.002_bib40","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"345","author":"Krystal","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib41","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1530-0277.2000.tb02107.x","article-title":"Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers","volume":"24","author":"McCaul","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"10.1016\/j.psc.2004.06.002_bib42","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1097\/01.ALC.0000095861.43232.19","article-title":"Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs","volume":"27","author":"Petrakis","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1360-0443.2003.00377.x","article-title":"Physicians' opinions about medications to treat alcoholism","volume":"98","author":"Mark","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.psc.2004.06.002_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4899-1678-5_13","article-title":"Serotonin uptake inhibitors attenuate ethanol intake in problem drinkers","volume":"7","author":"Naranjo","year":"1989","journal-title":"Recent Dev Alcohol"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1530-0277.1992.tb01373.x","article-title":"Effect of fluoxetine on alcohol consumption in male alcoholics","volume":"16","author":"Gorelick","year":"1992","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.152.3.391","article-title":"Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics","volume":"152","author":"Kranzler","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib47","first-page":"109","article-title":"Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics","volume":"11","author":"Janiri","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib48","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/clpt.1992.85","article-title":"Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers","volume":"51","author":"Naranjo","year":"1992","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2007-979538","article-title":"Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study","volume":"29","author":"Tiihonen","year":"1996","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1530-0277.1994.tb00093.x","article-title":"Effect of citalopram on alcohol intake in heavy drinkers","volume":"18","author":"Balldin","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1360-0443.1995.tb01013.x","article-title":"Effects of citalopram and a brief psycho\u2013social intervention on alcohol intake, dependence and problems","volume":"90","author":"Naranjo","year":"1995","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib52","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1530-0277.1996.tb01696.x","article-title":"Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics","volume":"20","author":"Kranzler","year":"1996","journal-title":"Alcohol Clin Exp Res"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib53","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","article-title":"Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence","volume":"24","author":"Johnson","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.psc.2004.06.002_bib54","doi-asserted-by":"crossref","first-page":"132S","DOI":"10.1111\/j.1530-0277.2001.tb02387.x","article-title":"Role of polyamines and NMDA receptors in ethanol dependence and withdrawal","volume":"25","author":"Littleton","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.psc.2004.06.002_bib55","first-page":"371090","article-title":"Acamprosate for the adjunctive treatment of alcohol dependence","author":"Overman","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib56","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199835050-00001","article-title":"Clinical pharmacokinetics of acamprosate","volume":"35","author":"Saivin","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.psc.2004.06.002_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1527-3458.2003.tb00260.x","article-title":"Pharmacology of acamprosate: an overview","volume":"9","author":"Zornoza","year":"2003","journal-title":"CNS Drug Rev"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.euroneuro.2003.08.009","article-title":"Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment","volume":"13","author":"Mason","year":"2003","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 20","key":"10.1016\/j.psc.2004.06.002_bib59","first-page":"42","article-title":"Treatment of alcohol-dependent outpatients with acamprosate: a clinical review","volume":"62","author":"Mason","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2004.06.002_bib61","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.ALC.0000078020.92938.0B","article-title":"Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study","volume":"27","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"Suppl 1","key":"10.1016\/j.psc.2004.06.002_bib62","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.2000.tb02164.x","article-title":"Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons","volume":"41","author":"Gibbs","year":"2000","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib63","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00171-X","article-title":"Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance","volume":"42","author":"Herrero","year":"2002","journal-title":"Neuropharmacology"},{"issue":"Suppl 1","key":"10.1016\/j.psc.2004.06.002_bib64","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"issue":"9370","key":"10.1016\/j.psc.2004.06.002_bib65","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02791072.1997.10400182","article-title":"Methadone maintenance treatment: the first thirty years","volume":"29","author":"Payte","year":"1997","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00213-002-1027-0","article-title":"High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans","volume":"161","author":"Donny","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psc.2004.06.002_bib68","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","article-title":"Methadone: a review of its pharmacokinetic\/pharmacodynamic properties","volume":"42","author":"Garrido","year":"1999","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib70","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0376-8716(93)90052-R","article-title":"Methadone dose and treatment outcome","volume":"33","author":"Strain","year":"1993","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-119-1-199307010-00004","article-title":"Dose-response effects of methadone in the treatment of opioid dependence","volume":"119","author":"Strain","year":"1993","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib72","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00007691-200110000-00010","article-title":"Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir","volume":"23","author":"Bart","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"9","key":"10.1016\/j.psc.2004.06.002_bib73","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1086\/322519","article-title":"Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users","volume":"33","author":"Clarke","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.psc.2004.06.002_bib74","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/00005053-198807000-00003","article-title":"Methadone maintenance to abstinence. How many make it?","volume":"176","author":"Milby","year":"1988","journal-title":"J Nerv Ment Dis"},{"issue":"22","key":"10.1016\/j.psc.2004.06.002_bib75","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/jama.280.22.1936","article-title":"Effective medical treatment of opiate addiction","volume":"280","author":"National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archpsyc.1976.01770060043007","article-title":"Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study","volume":"33","author":"Ling","year":"1976","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2004.06.002_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1300\/J069v20n04_02","article-title":"Torsades de pointes associated with high-dose levomethadyl acetate (ORLAAM)","volume":"20","author":"Deamer","year":"2001","journal-title":"J Addict Dis"},{"issue":"Suppl 2","key":"10.1016\/j.psc.2004.06.002_bib78","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 2","key":"10.1016\/j.psc.2004.06.002_bib79","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"18","key":"10.1016\/j.psc.2004.06.002_bib80","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.psc.2004.06.002_bib81","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1973.01750360022003","article-title":"Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man","volume":"28","author":"Martin","year":"1973","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib82","first-page":"524","article-title":"Effects of naltrexone on response to intravenous cocaine, hydromorphone, and their combination in humans","volume":"279","author":"Walsh","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.psc.2004.06.002_bib83","series-title":"The Cochrane Library, Issue 3","article-title":"Naltrexone maintenance treatment for opioid dependence (Cochrane Review)","author":"Kirchmayer","year":"2004"},{"issue":"8","key":"10.1016\/j.psc.2004.06.002_bib84","first-page":"835","article-title":"Naltrexone depot (drug abuse sciences)","volume":"5","author":"Modesto-Lowe","year":"2002","journal-title":"IDrugs"},{"key":"10.1016\/j.psc.2004.06.002_bib85","unstructured":"United States. Rockville (MD), Substance Abuse and Mental Health Services Administration. Office of Applied Studies. US Dept. of Health and Human Services Public Health Service; 2001."},{"key":"10.1016\/j.psc.2004.06.002_bib86","series-title":"The Cochrane Library, Issue 3","article-title":"Amantadine in Parkinson's disease (Cochrane Review)","author":"Crosby","year":"2004"},{"issue":"11","key":"10.1016\/j.psc.2004.06.002_bib87","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.2042-7158.1972.tb08906.x","article-title":"Effects of amantadine on uptake and release of dopamine by a particulate fraction of rat basal ganglia","volume":"24","author":"Heimans","year":"1972","journal-title":"J Pharm Pharmacol"},{"issue":"5581","key":"10.1016\/j.psc.2004.06.002_bib88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/264076a0","article-title":"Anticholinergic and membrane activities of amantadine in neuromuscular transmission","volume":"264","author":"Nastuk","year":"1976","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib89","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/0014-2999(92)90634-G","article-title":"The anti-Parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a noncompetitive way","volume":"213","author":"Stoof","year":"1992","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0376-8716(92)90004-V","article-title":"Amantadine may facilitate detoxification of cocaine addicts","volume":"31","author":"Alterman","year":"1992","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0376-8716(96)01225-2","article-title":"Amantadine in the early treatment of cocaine dependence: a double-blind, placebo-controlled trial","volume":"41","author":"Kampman","year":"1996","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"10.1016\/j.psc.2004.06.002_bib92","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1176\/appi.ajp.157.12.2052","article-title":"Amantadine in the treatment of cocaine-dependent patients with severe withdrawal symptoms","volume":"157","author":"Kampman","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib93","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0376-8716(01)00205-8","article-title":"A screening trial of amantadine as a medication for cocaine dependence","volume":"66","author":"Shoptaw","year":"2002","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.psc.2004.06.002_bib94","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1360-0443.1998.9357137.x","article-title":"Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram","volume":"93","author":"Carroll","year":"1998","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib95","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1360-0443.2000.9522198.x","article-title":"Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts","volume":"95","author":"Petrakis","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.psc.2004.06.002_bib96","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archpsyc.61.3.264","article-title":"Efficacy of disulfiram and cognitive-behavioral therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial","volume":"61","author":"Carroll","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib97","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1517\/14656566.2.1.179","article-title":"Pharmacology and clinical experience with tiagabine","volume":"2","author":"Schachter","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.psc.2004.06.002_bib98","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1046\/j.1360-0443.2003.00544.x","article-title":"Tiagabine increases cocaine-free urines in cocaine-dependent methadone treated patients: results of a randomized pilot study","volume":"98","author":"Gonz\u00e1lez","year":"2003","journal-title":"Addiction"},{"key":"10.1016\/j.psc.2004.06.002_bib99","unstructured":"Gonz\u00e1lez G, Sofuoglu M, Gonsai K, Poling J, Oliveto A, Kosten TR. Efficacy of tiagabine or gabapentin in reducing cocaine use in methadone-stabilized cocaine abusers. Presented at the College on Problems of Drug Dependence. 65th Annual Scientific Meeting. Bal Harbour, June 14--19, 2003."},{"issue":"4","key":"10.1016\/j.psc.2004.06.002_bib100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0301-0082(95)00012-K","article-title":"A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system","volume":"46","author":"Misgeld","year":"1995","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.psc.2004.06.002_bib101","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.1998.tb09740.x","article-title":"Neural systems underlying arousal and attention. Implications for drug abuse","volume":"846","author":"Robbins","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib102","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0376-8716(94)01083-W","article-title":"Pharmacological mechanisms in cocaine's cardiovascular effects","volume":"37","author":"Schindler","year":"1995","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.psc.2004.06.002_bib103","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0091-3057(99)00201-4","article-title":"Effects of labetalol treatment on the physiological and subjective response to smoked cocaine","volume":"65","author":"Sofuoglu","year":"2000","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0376-8716(00)80009-5","article-title":"Carvedilol affects the physiological and behavioral response to smoked cocaine in humans","volume":"60","author":"Sofuoglu","year":"2000","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.psc.2004.06.002_bib105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0376-8716(00)00193-9","article-title":"Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity","volume":"63","author":"Kampman","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.psc.2004.06.002_bib106","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunization","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.psc.2004.06.002_bib107","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/nm1096-1129","article-title":"Efficacy of a therapeutic cocaine vaccine in rodent models","volume":"2","author":"Fox","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.psc.2004.06.002_bib108","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0376-8716(97)00121-X","article-title":"Development of a therapeutic vaccine for the treatment of cocaine addiction","volume":"48","author":"Fox","year":"1997","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.psc.2004.06.002_bib109","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0264-410X(01)00425-X","article-title":"Human therapeutic cocaine vaccine: safety and immunogenicity","volume":"20","author":"Kosten","year":"2002","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.psc.2004.06.002_bib110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s002130050049","article-title":"Evaluation of anticocaine antibodies and a cocaine vaccine in a rat self-administration model","volume":"148","author":"Kantak","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.psc.2004.06.002_bib111","unstructured":"Kosten TR. Cocaine vaccines. Presented at the College on Problems of Drug Dependence. 65th Annual Scientific Meeting. Bal Harbour, June 14--19, 2003."}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X04000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X04000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T05:27:48Z","timestamp":1548566868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X04000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0193953X04000577"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2004.06.002","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}